LaFleur & Godfrey LLC lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 29.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 79,127 shares of the biopharmaceutical company’s stock after selling 32,344 shares during the quarter. Gilead Sciences comprises about 1.3% of LaFleur & Godfrey LLC’s portfolio, making the stock its 29th biggest holding. LaFleur & Godfrey LLC’s holdings in Gilead Sciences were worth $5,144,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds also recently bought and sold shares of GILD. Bank of New York Mellon Corp raised its position in Gilead Sciences by 199,789.8% in the third quarter. Bank of New York Mellon Corp now owns 31,350,714 shares of the biopharmaceutical company’s stock worth $2,420,587,000 after acquiring an additional 31,335,030 shares in the last quarter. Macquarie Group Ltd. raised its position in Gilead Sciences by 6.9% in the third quarter. Macquarie Group Ltd. now owns 443,302 shares of the biopharmaceutical company’s stock worth $34,228,000 after acquiring an additional 28,450 shares in the last quarter. Kentucky Retirement Systems bought a new stake in Gilead Sciences in the third quarter worth about $9,514,000. Teachers Advisors LLC raised its position in Gilead Sciences by 3.6% in the third quarter. Teachers Advisors LLC now owns 4,879,609 shares of the biopharmaceutical company’s stock worth $376,755,000 after acquiring an additional 169,335 shares in the last quarter. Finally, TIAA CREF Investment Management LLC raised its position in Gilead Sciences by 21.1% in the third quarter. TIAA CREF Investment Management LLC now owns 10,241,394 shares of the biopharmaceutical company’s stock worth $790,738,000 after acquiring an additional 1,786,881 shares in the last quarter. 80.20% of the stock is owned by institutional investors and hedge funds.
NASDAQ GILD opened at $62.95 on Friday. The company has a debt-to-equity ratio of 1.19, a quick ratio of 3.30 and a current ratio of 3.38. The stock has a market cap of $80.29 billion, a price-to-earnings ratio of 10.24, a P/E/G ratio of 4.19 and a beta of 1.16. Gilead Sciences, Inc. has a 1 year low of $60.32 and a 1 year high of $79.61.
The firm also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.00%. The ex-dividend date was Thursday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.57. Gilead Sciences’s payout ratio is 40.98%.
In other Gilead Sciences news, Director John Francis Cogan sold 2,700 shares of Gilead Sciences stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $67.23, for a total transaction of $181,521.00. Following the transaction, the director now owns 57,560 shares of the company’s stock, valued at approximately $3,869,758.80. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Richard James Whitley sold 9,534 shares of Gilead Sciences stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $65.48, for a total value of $624,286.32. Following the transaction, the director now directly owns 34,669 shares in the company, valued at approximately $2,270,126.12. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 42,102 shares of company stock worth $2,787,375. Company insiders own 0.20% of the company’s stock.
Several brokerages have commented on GILD. Zacks Investment Research upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, April 9th. Oppenheimer set a $85.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a report on Tuesday, March 19th. Mizuho set a $88.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a report on Friday, April 12th. Maxim Group restated a “buy” rating and set a $84.00 price objective on shares of Gilead Sciences in a report on Friday, March 29th. Finally, UBS Group upgraded Gilead Sciences from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $75.00 to $77.00 in a report on Wednesday, April 10th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $82.12.
ILLEGAL ACTIVITY WARNING: This report was reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.baseballdailydigest.com/news/2019/04/21/gilead-sciences-inc-gild-shares-sold-by-lafleur-godfrey-llc.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
Recommended Story: How interest rates affect municipal bond prices
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.